AstraZeneca PLC (AZN) Stock

About AstraZeneca PLC

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

AstraZeneca PLC is led by CEO Pascal Claude Roland Soriot, employs 94,300 people, headquartered in Cambridge, GB, publicly traded since 1993.

AstraZeneca PLC (AZN) stock trades at $173.30 with a market capitalization of $134.31B. The stock is valued at a price-to-earnings (P/E) ratio of 29.74, price-to-book of 5.93, price-to-sales of 4.63. Over the past 52 weeks the stock has ranged between $137.22 and $212.71, and currently trades 18.5% below its 52-week high. It pays a dividend yielding 1.69%.

On profitability, AstraZeneca PLC generates a return on equity (ROE) of 22.68% — well above the market average, a sign of a high-quality business, return on capital employed of 28.21%, an operating margin of 23.28%, a net profit margin of 17.19%.

In its most recent fiscal year, AstraZeneca PLC reported annual revenue of $58.7B, net profit of $10.3B, revenue has compounded at 17.2% a year over the last five years, profit at 26.3% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.72, a current ratio of 0.94, total assets of $114.1B, $5.7B in cash and equivalents.

AZN has an average daily trading volume of 2,266,811 shares, a beta of 0.21 (less volatile than the overall market).

Official website: www.astrazeneca.com